Servier's Innovative Tibsovo Program Expands for IDH1-Mutated Cancer Treatments This article discusses Servier's advancements in its Tibsovo development program targeting IDH1-mutated cancers, focusing on new clinical trials and patient enrollment updates.

Servier's Innovative Tibsovo Program Expands for IDH1-Mutated Cancer Treatments #United_States #Boston #Servier #Tibsovo #IDH1_mutation